Full-Time

Associate Director

Toxicology

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

AI & Machine Learning
Biotechnology

Compensation Overview

$174k - $190kAnnually

+ Bonus + Equity Compensation

Senior, Expert

New York, NY, USA + 1 more

More locations: Hayward, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • PhD in Toxicology, Pharmacology, or a related field with 8+ years of relevant experience.
  • Prior experience monitoring studies or acting as study director at CRO.
  • Strong track record of pharmaceutical drug discovery and development experience, success and leadership, exemplified by advancement of programs to IND filing. Marketing application expertise a plus.
  • Demonstrated excellence in oral and written communication skills.
  • In-depth knowledge of FDA, EMA, and ICH guidelines, including experience in the preparation of regulatory documents and knowledge of regulatory guidance.
Responsibilities
  • Serve as toxicology expert to discovery and development teams.
  • Work cross-functionally with research teams to design exploratory and GLP compliant toxicology studies to investigate properties of candidate compounds.
  • Design and implement regulatory toxicology studies at contract research labs, acting as study monitor, to support development of candidate and clinical stage molecules.
  • Analyze and interpret data, determine next steps, and communicate results to development teams and management.
  • Author regulatory submissions documents (IB, IND, BLA, Annual Reports) as needed to support development programs, represent toxicology function in meetings with regulatory agencies.
  • Maintain currency with internal training and global regulatory requirements.
  • Travel to CRO sites during study conduct to ensure regulatory compliance and effective execution of study protocols.

Eikon Therapeutics develops new medicines in the pharmaceutical industry by studying biological systems to identify drug targets. They utilize a proprietary single-molecule tracking platform to visualize protein movements in living cells, combined with artificial intelligence and automation for precise molecular interaction analysis. Their diverse team integrates various scientific and engineering disciplines to create therapies aimed at improving the lives of patients with serious diseases. Eikon stands out from competitors by focusing on the dynamic aspects of biology rather than static chemical processes.

Company Stage

Series C

Total Funding

$750.8M

Headquarters

Hayward, California

Founded

2019

Growth & Insights
Headcount

6 month growth

7%

1 year growth

14%

2 year growth

62%
Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon's recent acquisition of global rights to clinical-stage assets and a robust drug development pipeline positions it for significant growth and market impact.
  • The company's strategic partnerships, such as with Impact Therapeutics for PARP1 selective inhibitors, enhance its capabilities in developing targeted cancer therapies.
  • Eikon's expansion into a new 36,284-square-foot office space in Jersey City reflects its growth and commitment to scaling operations.

What critics are saying

  • The highly competitive biotech and pharmaceutical sectors require continuous innovation to maintain a competitive edge.
  • The integration of newly acquired assets and technologies may pose challenges in terms of operational alignment and resource allocation.

What makes Eikon Therapeutics unique

  • Eikon Therapeutics leverages proprietary single-molecule tracking (SMT) technology to visualize protein motion in living cells, setting it apart from competitors who rely on static snapshots of chemical processes.
  • The integration of advanced automation and artificial intelligence allows Eikon to inventory molecular interactions with unprecedented scale and precision.
  • Eikon's diverse team of scientists, engineers, and clinicians enables a multidisciplinary approach to drug development, enhancing innovation and problem-solving capabilities.

Help us improve and share your feedback! Did you find this helpful?